PHARMACY

FDA approves Mylan’s generic Risperdal

BY Alaric DeArment

PITTSBURGH The Food and Drug Administration has approved Mylan’s generic version of Johnson & Johnson’s antipsychotic drug Risperdal, Mylan announced Tuesday.

Mylan will market risperidone tablets USP in 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg and 4 mg doses. The drug is approved for treating schizophrenia and bipolar disorder, and Mylan said it would begin shipping the tablets shortly.

The branded version of the drug had sales of about $2.67 billion in the United States during the 12 months ended June 30, according to IMS Health.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

Bayer denies takeover rumors

BY Alaric DeArment

FRANKFURT, Germany Reports of Bayer’s imminent takeover appear greatly exaggerated.

The company’s chief executive officer told a German newspaper that it would not be taken over, amid rumors last week that Pfizer sought to acquire it. But Bayer has a number of drugs in its research pipeline, while many of Pfizer’s blockbuster drugs will soon go off patent, facing competition from generic drug makers.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

MyMedSchedule now available to the public

BY Alaric DeArment

INDIANAPOLIS A service that helps people with organ transplants manage their medication schedules has become available to the public.

MyMedSchedule used to be available only in hospitals, reminding organ transplant recipients to take their medications and helping them avoid errors. People who have received transplants often must take several drugs to avoid rejection of the new organs.

Companies such as Community Health Network and the American Society of Health-System Pharmacists offer similar services.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?